AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm in Chronic Lung Diseases

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Grenoble
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

PNEUMO-LIBS is a multicenter, non-interventional observational study designed to evaluate whether multi-element tissue imaging by Laser-Induced Breakdown Spectroscopy (LIBS), combined with an artificial intelligence-based analysis tool called Interesting Features Finder (IFF), may help physicians better understand the possible causes of chronic lung diseases. The study focuses on adult patients with chronic lung diseases for which a lung biopsy has already been performed as part of routine medical care. These diseases include diffuse interstitial lung diseases, pulmonary granulomatoses such as sarcoidosis, and emphysema, especially when an environmental or occupational exposure is suspected but not clearly demonstrated. Some chronic lung diseases may be influenced by inhaled mineral or metallic particles, such as silica, aluminum, titanium, or other metals. However, these exposures are

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adult patient aged 18 years or older. * Diagnosis or documented clinical suspicion of chronic lung disease, including interstitial lung disease, pulmonary granulomatosis such as sarcoidosis, or pulmonary emphysema. * Availability of a lung tissue biopsy sample obtained during routine medical care and stored as a formalin-fixed paraffin-embedded sample. * Sufficient medical record information to document the clinical context, occupational or environmental exposure history, smoking status, imaging, pathology reports, and other relevant routine-care data. * No documented objection to the secondary use of health data and biological samples for this research. Exclusion Criteria: * Documented objection to participation in the study or to the secondary use of health data or biological samples for research. * Missing, unavailable, degraded, or technically unusable biopsy sample. * Insufficient medical record information to document the clinical context or exposure history. * Lung condition outside the scope of the study, such as isolated acute infection, isolated cardiac disease, or primary lung cancer. * Patient under legal protection when the applicable legal conditions for non-opposition cannot be fulfilled.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

3 sites
CHU Grenoble Alpes
Grenoble, France
Centre Hospitalier Rรฉgional Universitaire Nancy (CHRU)
Nancy, France
centre Hospitalier Universitaire Rouen (CHU)
Rouen, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy